2.57
price up icon27.23%   0.55
 
loading
前日終値:
$2.02
開ける:
$2.12
24時間の取引高:
2.59M
Relative Volume:
6.15
時価総額:
$215.58M
収益:
$3.91M
当期純損益:
$-206.53M
株価収益率:
-1.0352
EPS:
-2.4825
ネットキャッシュフロー:
$-167.78M
1週間 パフォーマンス:
+2.80%
1か月 パフォーマンス:
+147.12%
6か月 パフォーマンス:
+192.05%
1年 パフォーマンス:
+52.07%
1日の値動き範囲:
Value
$2.09
$2.85
1週間の範囲:
Value
$2.00
$2.95
52週間の値動き範囲:
Value
$0.595
$3.075

I Mab Adr Stock (IMAB) Company Profile

Name
名前
I Mab Adr
Name
セクター
Healthcare (1174)
Name
電話
-
Name
住所
-
Name
職員
32
Name
Twitter
Name
次回の収益日
2025-03-31
Name
最新のSEC提出書
Name
IMAB's Discussions on Twitter

IMAB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IMAB
I Mab Adr
2.57 215.58M 3.91M -206.53M -167.78M -2.4825
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

I Mab Adr Stock (IMAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-12-09 開始されました Siebert Williams Shank Buy
2021-06-02 開始されました Daiwa Securities Buy
2021-03-15 開始されました Needham Buy
2021-03-03 繰り返されました H.C. Wainwright Buy
2021-02-25 開始されました Piper Sandler Overweight
2020-12-07 開始されました H.C. Wainwright Buy
2020-07-27 開始されました Cantor Fitzgerald Overweight
2020-02-12 開始されました China Renaissance Buy
2020-02-11 開始されました Jefferies Buy
すべてを表示

I Mab Adr (IMAB) 最新ニュース

pulisher
Jun 17, 2025

I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX

Jun 17, 2025
pulisher
Jun 13, 2025

I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net

Jun 11, 2025
pulisher
Jun 11, 2025

Willdan Group, Inc.'s (NASDAQ:WLDN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Can This Unstoppable Stock Join Microsoft, Nvidia, Apple, Amazon, Alphabet, Meta Platforms, and Tesla in the $1 Trillion Club? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

Graphjet Technology Discloses Notice from Nasdaq - Yahoo Finance

Jun 10, 2025
pulisher
Jun 07, 2025

B. Riley Financial granted extension from Nasdaq regarding listing rules - Yahoo Finance

Jun 07, 2025
pulisher
Jun 06, 2025

I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise

Jun 06, 2025
pulisher
Jun 06, 2025

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance

Jun 06, 2025
pulisher
Jun 05, 2025

Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize

Jun 05, 2025
pulisher
Jun 05, 2025

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance

Jun 05, 2025
pulisher
Jun 03, 2025

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance

Jun 03, 2025
pulisher
May 28, 2025

I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com

May 28, 2025
pulisher
May 28, 2025

Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com

May 28, 2025
pulisher
May 17, 2025

I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks

May 17, 2025
pulisher
May 15, 2025

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

May 15, 2025
pulisher
May 06, 2025

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com

May 06, 2025
pulisher
May 05, 2025

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com

May 05, 2025
pulisher
Apr 14, 2025

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 14, 2025
pulisher
Apr 11, 2025

After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance

Apr 11, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 04, 2025

I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks

Apr 04, 2025
pulisher
Apr 04, 2025

I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.

Apr 03, 2025
pulisher
Apr 03, 2025

I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com

Apr 03, 2025
pulisher
Mar 21, 2025

I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

I-Mab faces Nasdaq delisting over bid price rule - Investing.com

Mar 21, 2025
pulisher
Mar 07, 2025

I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com

Mar 07, 2025
pulisher
Mar 05, 2025

I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India

Mar 05, 2025
pulisher
Feb 17, 2025

I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News

Feb 17, 2025
pulisher
Feb 07, 2025

Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature

Feb 07, 2025
pulisher
Jan 08, 2025

I-Mab Chairman plans $2 million ADS purchase - Investing.com India

Jan 08, 2025
pulisher
Nov 15, 2024

I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - TipRanks

Nov 15, 2024
pulisher
Nov 06, 2024

I-Mab names Sean Fu as new CEO - Investing.com

Nov 06, 2024
pulisher
Oct 09, 2024

IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Oct 09, 2024
pulisher
Jun 05, 2024

I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks

Jun 05, 2024
pulisher
Mar 18, 2024

Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com

Mar 18, 2024
pulisher
Mar 12, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 12, 2024
pulisher
Jan 31, 2024

Seagen acquisition will give Pfizer 'anchor asset' that Wall Street desires: CEO Bourla - Yahoo Finance

Jan 31, 2024
pulisher
Sep 27, 2023

How to Use the 50 and 200-Day Moving Averages - Yahoo Finance

Sep 27, 2023
pulisher
Sep 09, 2023

Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature

Sep 09, 2023
pulisher
Aug 17, 2023

I-Mab: Dropping Coverage - Morningstar

Aug 17, 2023

I Mab Adr (IMAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
大文字化:     |  ボリューム (24 時間):